Skip to main content

Danish Array Firm Exiqon Jettisons Sales Staff, Shutters US Office

NEW YORK, May 31 - Danish microarray company Exiqonsaid today it has cut its staff and closed its US sales office.

 

Though it was not immediately clear how many people lost their jobs, the cuts come mainly from sales and marketing with a smaller number coming from the R&D side, according to Lars Kongsbak, Exiqon's vice president for business development, science, and technology.

 

The Vedbaek-based maker of microarrays, microplates, and locked nucleic acids is now pursuing "an M&A strategy," said Kongsbak. "Instead of trying to sell our products ourselves we are now looking for partners who will take that on."

 

Kongsback said the cuts and shift in strategy were motivated principally by the fact that the company' could not see an IPO in the near future, leaving its venture capital backers with no viable exit strategy.

 

An in-depth version of this article can be read next week on BioArray News.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.